{"id":4405,"date":"2021-11-09T16:34:34","date_gmt":"2021-11-10T00:34:34","guid":{"rendered":"https:\/\/keck.usc.edu\/news\/124653-2\/"},"modified":"2023-11-26T08:38:03","modified_gmt":"2023-11-26T16:38:03","slug":"124653-2","status":"publish","type":"post","link":"https:\/\/keck.usc.edu\/news\/124653-2\/","title":{"rendered":"Botulinum Toxin Type A Helps with Bruxism"},"content":{"rendered":"\n \n \n\n\n\n\n\n\n\n
\n\n \n
\n \n
\n\n \n Press Release<\/span>\n\n\n\n<\/div>\n \n \n
\n\n \n

Botulinum Toxin Type A Helps with Bruxism<\/h1>\n\n\n<\/div>\n \n \n
\n \n November 09, 2021<\/span>\n <\/div>\n \n \n
\n\n \n
<\/path><\/svg><\/span><\/a><\/path><\/svg><\/span><\/a><\/path><\/svg><\/span><\/a><\/path><\/path><\/path><\/svg><\/span><\/a><\/path><\/svg><\/span><\/a><\/path><\/path><\/g><\/svg><\/span><\/a><\/svg><\/span><\/a><\/div>
<\/div><\/div>\n\n\n<\/div>\n \n <\/div>\n\n \n
\n\n \n \n \n \n \n \n \n \n\n \n \n \n \n\n<\/div>\n \n\n <\/div><\/div>\n\r\n\r\n\n\n \n \n\n\n\n\n\n\n\n
\n\n \n
\n \n
\n\n \n
\n

According to\u00a0the Sleep Foundation<\/a>, up to 50% of children experience sleep bruxism, around 15% of adolescents do, and around 8% of adults experience the condition [1]. Bruxism, when someone has an involuntary habit of clenching and grinding their teeth, can lead to chronic pain. The good news is that there are things that can help with the condition. One of the most recent findings on what can help points to the use of low-dose botulinum toxin A to bring relief.<\/p>\n

Some people experience bruxism while they are sleeping, while others tend to do it during awake hours. The continuous grinding and clenching of the teeth can lead to more serious issues, including a condition called temporomandibular disorder. This condition impacts the nerves that are linked to chronic facial pain.<\/p>\n

Researchers set out to see if using botulinum toxin could help bring relief for the chronic pain that those with bruxism and temporomandibular disorder experience. Botulinum toxin type A, which is a medicinal form of Botox, is a neurotoxin that paralyzes the nerves that are involved. The findings of their study are published in the September 2021 issue of\u00a0Cranio: The Journal of Craniomandibular Practice<\/i><\/a>\u00a0[2].<\/p>\n

In the study, 35 patients with chronic pain from sleep bruxism, awake bruxism, and temporomandibular disorder participated. The participants each received a single dose of low-dose botulinum toxin type A in their cheek muscle. The participants were given a pain assessment before receiving the treatment, as well as after 15, 30, 60, 90, and 180 days.<\/p>\n

Share this:<\/h3>\n
\n